Prime Medicine, Inc. (PRME)
Automate Your Wheel Strategy on PRME
With Tiblio's Option Bot, you can configure your own wheel strategy including PRME - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRME
- Rev/Share 0.0372
- Book/Share 1.0082
- PB 3.7889
- Debt/Equity 0.73
- CurrentRatio 6.608
- ROIC -0.5702
- MktCap 676146364.0
- FreeCF/Share -0.6666
- PFCF -6.3192
- PE -3.1069
- Debt/Assets 0.3068
- DivYield 0
- ROE -1.6351
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PRME | Citigroup | Buy | Neutral | -- | $1.5 | May 27, 2025 |
| Downgrade | PRME | H.C. Wainwright | Buy | Neutral | -- | -- | May 20, 2025 |
| Downgrade | PRME | JP Morgan | Overweight | Neutral | -- | -- | May 20, 2025 |
| Initiation | PRME | JMP Securities | -- | Mkt Outperform | -- | $10 | Dec. 10, 2024 |
News
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript
Published: November 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Prime Medicine, Inc. ( PRME ) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST Company Participants Gregory Dearborn Allan Reine - CEO & Director Mohammed Asmal Conference Call Participants Michael Schilsky Maurice Raycroft - Jefferies LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Troy Langford David Nierengarten - Wedbush Securities Inc., Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Presentation Gregory Dearborn Good morning, everyone, and welcome to …
Read More
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 --
Read More
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago.
Read More
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.46 per share a year ago.
Read More
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Prime Medicine, Inc. (PRME) could be a good stock pick from a technical perspective. PRME recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
An updated edition of the June 27, 2025, article.
Read More
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --
Read More
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Read More
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.
Read More
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
Read More
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D.
Read More
About Prime Medicine, Inc. (PRME)
- IPO Date 2022-10-20
- Website https://www.primemedicine.com
- Industry Biotechnology
- CEO Allan Reine
- Employees 214